Research Comparison
KLOW Stack (GHK-Cu + TB-500 + BPC-157 + KPV) vs KPV (Lys-Pro-Val)
A side-by-side research comparison of KLOW Stack (GHK-Cu + TB-500 + BPC-157 + KPV) and KPV (Lys-Pro-Val) drawn from Cobalt Peptides' peptide database records.
KLOW Stack (GHK-Cu + TB-500 + BPC-157 + KPV)
The KLOW Protocol is a four-peptide regenerative blend combining GHK-Cu, TB-500 (Thymosin Beta-4), BPC-157, and KPV. It builds upon the GLOW protocol by incorporating KPV, a tripeptide with anti-inflammatory activity, to enhance tolerability and broaden mechanistic coverage. Typical formulations contain approximately 50mg GHK-Cu, 10mg TB-500, 10mg BPC-157, and 10mg KPV in a 5:1:1:1 ratio. While individual peptides have established research backgrounds, no clinical trials have evaluated this specific combination, and all effects remain theoretical based on additive and complementary mechanisms.
KPV (Lys-Pro-Val)
KPV (Lys-Pro-Val) is a tripeptide derived from the C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH). Unlike the parent hormone, KPV retains potent anti-inflammatory and immunomodulatory activity without inducing melanogenesis or pigmentation. It has been investigated for its ability to modulate inflammatory pathways at the cellular level, with particular relevance to inflammatory bowel disease, dermatological conditions, and systemic inflammation. Its small size enables efficient cellular penetration and direct interaction with intracellular signaling pathways.